Icon Advisers Inc. Co. increased its stake in Amneal Pharmaceuticals Inc (NYSE:AMRX) by 11.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 32,500 shares of the company’s stock after buying an additional 3,300 shares during the quarter. Icon Advisers Inc. Co.’s holdings in Amneal Pharmaceuticals were worth $721,000 as of its most recent filing with the SEC.
Other hedge funds also recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in shares of Amneal Pharmaceuticals in the second quarter valued at about $120,000. Neuburgh Advisers LLC acquired a new stake in shares of Amneal Pharmaceuticals in the second quarter valued at about $123,000. Great West Life Assurance Co. Can acquired a new stake in shares of Amneal Pharmaceuticals in the second quarter valued at about $130,000. Sei Investments Co. acquired a new stake in shares of Amneal Pharmaceuticals in the second quarter valued at about $139,000. Finally, Riverhead Capital Management LLC acquired a new stake in shares of Amneal Pharmaceuticals in the second quarter valued at about $141,000. Institutional investors and hedge funds own 31.84% of the company’s stock.
A number of equities research analysts have weighed in on AMRX shares. B. Riley raised their price objective on Amneal Pharmaceuticals from $26.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, August 22nd. Canaccord Genuity restated a “hold” rating and set a $21.00 price objective on shares of Amneal Pharmaceuticals in a research note on Monday, August 20th. ValuEngine lowered Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 27th. Morgan Stanley lowered their price objective on Amneal Pharmaceuticals from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Wednesday, October 3rd. Finally, Royal Bank of Canada upgraded Amneal Pharmaceuticals from a “sector perform” rating to an “outperform” rating in a research note on Monday, August 13th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $22.75.
Shares of NYSE AMRX opened at $19.75 on Friday. Amneal Pharmaceuticals Inc has a fifty-two week low of $13.47 and a fifty-two week high of $24.48. The company has a quick ratio of 1.25, a current ratio of 2.01 and a debt-to-equity ratio of 2.85. The company has a market cap of $6.14 billion, a price-to-earnings ratio of 31.35, a price-to-earnings-growth ratio of 1.01 and a beta of 1.56.
Amneal Pharmaceuticals (NYSE:AMRX) last issued its quarterly earnings data on Wednesday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Amneal Pharmaceuticals had a positive return on equity of 6.62% and a negative net margin of 36.54%. The firm had revenue of $476.50 million during the quarter, compared to analyst estimates of $486.01 million. The business’s revenue for the quarter was up 87.1% on a year-over-year basis. Equities analysts expect that Amneal Pharmaceuticals Inc will post 0.91 earnings per share for the current fiscal year.
In other news, SVP Nikita Shah sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $23.46, for a total value of $1,173,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Bryan M. Reasons sold 11,698 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $23.65, for a total value of $276,657.70. The disclosure for this sale can be found here. 3.20% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Icon Advisers Inc. Co. Buys 3,300 Shares of Amneal Pharmaceuticals Inc (AMRX)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/11/10/icon-advisers-inc-co-buys-3300-shares-of-amneal-pharmaceuticals-inc-amrx.html.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
Featured Article: How to interpret a stock’s beta number
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.